Boceprevir for Untreated Chronic HCV Genotype 1 InfectionPOORDAD, Fred; MCCONE, Jonathan; DINUBILE, Mark J et al.The New England journal of medicine. 2011, Vol 364, Num 13, pp 1195-1206, issn 0028-4793, 12 p.Article

Racial Differences in Hepatitis C Treatment EligibilityMELIA, Michael T; MUIR, Andrew J; MULLEN, Kevin D et al.Hepatology (Baltimore, Md.). 2011, Vol 54, Num 1, pp 70-78, issn 0270-9139, 9 p.Article

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionMCHUTCHISON, John G; LAWITZ, Eric J; GALATI, Joseph S et al.The New England journal of medicine. 2009, Vol 361, Num 6, pp 580-593, issn 0028-4793, 14 p.Article

Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialOGERT, Robert A; HOWE, John A; RAVENDHRAN, Natarajan et al.Antiviral therapy (London). 2013, Vol 18, Num 3, pp 387-397, issn 1359-6535, 11 p.Article

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patientsTHOMPSON, Alexander J; CLARK, Paul J; NAGGIE, Susanna et al.Journal of hepatology. 2012, Vol 56, Num 2, pp 313-319, issn 0168-8278, 7 p.Article

Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1JACOBSON, Ira M; BROWN, Robert S; GALLER, Greg W et al.Hepatology (Baltimore, Md.). 2007, Vol 46, Num 4, pp 982-990, issn 0270-9139, 9 p.Article